2022
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefits
2018
PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer
Hou Y, Nitta H, Wei L, Banks P, Lustberg M, Wesolowski R, Ramaswamy B, Parwani A, Li Z. PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer. The Breast Journal 2018, 24: 911-919. PMID: 30230111, PMCID: PMC6724200, DOI: 10.1111/tbj.13112.Peer-Reviewed Original ResearchConceptsPD-L1 expressionCD8-positive T cellsTumor-infiltrating lymphocytesHER2-positive casesLymph node metastasisCytotoxic immune reactionsBreast carcinomaImmune reactionsNode metastasisPD-L1Immune cellsConventional chemotherapyBreast cancerT cellsTissue microarrayHER2-positive invasive breast cancerHER2-positive invasive breast carcinomasHER2-positive breast cancerHER2-positive breast carcinomasTumor cellsPD1/PD-L1 expressionHigh Nottingham gradePD-L1 stainingInvasive breast cancerLower tumor stageAn Evaluation of Factors Predicting Diet Quality among Cancer Patients
Kane K, Ilic S, Paden H, Lustberg M, Grenade C, Bhatt A, Diaz D, Beery A, Hatsu I. An Evaluation of Factors Predicting Diet Quality among Cancer Patients. Nutrients 2018, 10: 1019. PMID: 30081543, PMCID: PMC6116020, DOI: 10.3390/nu10081019.Peer-Reviewed Original ResearchConceptsHealthy Eating Index 2010Higher HEI scoresCancer patientsHEI scoresDiet qualityMean HEI scoreLower HEI scoresDisease-related factorsDisease-related characteristicsOverall HEI scoreHigher diet qualityTypes of cancerGeneral education diplomaPredictive factorsCancer mortalityPoor-quality dietLower riskPatientsHealthcare providersSpecific demographic characteristicsHigh school degreeDemographic characteristicsOne-way ANOVAScoresCancer
2015
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells
Oliveira-Costa J, de Carvalho A, da Silveira G, Amaya P, Wu Y, Park K, Gigliola M, Lustberg M, Buim M, Ferreira E, Kowalski L, Chalmers J, Soares F, Carraro D, Ribeiro-Silva A. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015, 6: 20902-20920. PMID: 26041877, PMCID: PMC4673238, DOI: 10.18632/oncotarget.3939.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAutoimmune DiseasesB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellCohort StudiesCytoplasmDNA-Binding ProteinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMouth NeoplasmsNeoplastic Cells, CirculatingOligonucleotide Array Sequence AnalysisPrognosisProportional Hazards ModelsTissue BanksTreatment OutcomeConceptsOral squamous cell carcinomaPD-L1Tumor sizePerineural invasionPrimary tumorAdvanced oral squamous cell carcinomaTumor cellsSquamous cell carcinoma developmentStrong cytoplasmatic expressionPD-L1 positivityDisease-specific survivalOral squamous cell carcinoma developmentPD-L1 expressionIndependent prognostic factorLymph node metastasisT cell activitySquamous cell carcinomaSub-classify patientsSpecific survivalNode metastasisPD-1Prognostic factorsPoor prognosisAutoimmune diseasesCell carcinoma
2011
Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
Lustberg M, Povoski S, Zhao W, Ziegler R, Sugimoto Y, Ruppert A, Lehman A, Shiels D, Mrozek E, Ramaswamy B, Layman R, Brueggemeier R, Shapiro C. Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer 2011, 11: 221-227. PMID: 21729671, PMCID: PMC3440773, DOI: 10.1016/j.clbc.2011.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrostadienesAntineoplastic AgentsBreast NeoplasmsCarcinoma, LobularCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLymphatic MetastasisMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPostmenopausePyrazolesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSulfonamidesSurvival RateTreatment OutcomeConceptsPathological complete responsePhase II trialEstrogen receptorKi-67Neoadjuvant exemestaneII trialPostmenopausal womenCOX-2Breast cancerDefinitive breast cancer surgeryCOX-2 inhibitor celecoxibSerious cardiac eventsAnti-tumor responseBreast cancer surgeryAddition of celecoxibCOX-2 expressionMajority of womenStable diseaseCardiac eventsPartial responseComplete responseCancer surgeryCore biopsyAromatase inhibitorsHER-2